secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2026-09-16T20:32:09+00:00
Accession:  0001159036-26-000121
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme announces $1.05B convertible notes offering due 2033
-------------------------------------------------------------

- Offering of $1.05B aggregate principal of convertible senior notes due 2033, unsecured, semi-annual interest, maturing Oct 1, 2033.
- 13-day option for initial purchasers to buy up to $150M additional notes, for potential total of $1.2B.
- Proceeds to fund capped call transactions, repurchase existing 0.25% 2027 and 1.00% 2028 convertible notes, and general corporate purposes.
- Capped calls intended to reduce dilution; concurrent note repurchases may affect common stock price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000121/0001159036-26-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000121/halo-20260916.htm
  HTML page:      https://secwatch.observer/filing/0001159036-26-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer